Search
Selected Filters
Filter Results
Displaying 51–60 of 64 news results
-
Jul 11, 2019
Gene Therapy Trials for Wet Age-Related Macular Degeneration
After a series of failed trials, current research suggests that the next generation of gene therapies for wet age-related macular degeneration holds promise. Learn how investigators are inducing the body’s cells to administer their own therapeutic response to disease activity.
-
Jun 3, 2019
Tackling the Next Gene Therapy Challenge: Autosomal Dominant Diseases
A discussion of strategies concerning the development of autosomal dominant disease therapies at the Translational Research Acceleration Program (TRAP) in November 2013.
-
Mar 7, 2019
The Foundation Fighting Blindness and Dr. H. James & Carole Free Collaborate to Combat AMD
Age-related macular degeneration (AMD) is the leading cause of blindness for people over 50 years of age in developed countries.
-
Oct 18, 2018
FFB Congratulates RPE65 Gene Therapy Researchers for Champalimaud Award
More than two decades ago, the Foundation Fighting Blindness (FFB) began funding RPE65 gene therapy research that led in late 2017 to LUXTURNA™, the first FDA-approved gene therapy for the eye or an inherited condition. Ultimately, the Foundation provided more than $10 million in funding for the groundbreaking effort.
-
Jan 18, 2018
The Assistance Fund Opens New Program for Inherited Retinal Diseases
The Assistance Fund, an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs, today launched a new program that offers financial support for individuals with inherited retinal diseases.
-
Jan 9, 2018
A Retinal Research Nonprofit Paves the Way for Commercializing Gene Therapies
AN EMERGING, vision-restoring gene therapy for a devastating retinal disease is poised for Food and Drug Administration (FDA) approval. If it gets the regulatory nod, it will be the first gene therapy to receive FDA approval for the eye or an inherited condition.
-
Oct 12, 2017
Investigational LUXTURNA has the potential to be both the first pharmacologic treatment for an inherited retinal disease (IRD) and the first gene therapy for a genetic disease in the United States
First adeno-associated viral (AAV) vector investigational candidate to reach this stage of FDA review
Investigational LUXTURNA clinical program includes up to four years of efficacy data, with observation ongoing
-
Apr 13, 2016
Foundation Fighting Blindness Announces Leadership Succession Plan After 45 Year Legacy
David Brint has been elected Chairman, effective July 1, 2016. Brint succeeds co-founder and current Chairman, Gordon Gund, who will remain a member of the Board of Directors and will continue to be actively involved in the Foundation’s Research Oversight Committee
-
Oct 1, 2015
The Challenge Continues: FFB Chairman Gordon Gund is Interviewed on CNBC
In a recent interview with CNBC’ s Brian Sullivan, during a tech-investor conference in Nantucket, Gordon explained why this is such a crucial time in retinal-research history.
-
Jan 14, 2014
Vision Improvements Reported in Choroideremia Gene Therapy Clinical Trial
Five of six participants in the initial study group have sustained vision improvements in their treated eyes in dim settings.